

Table 3. Risk of VTE associated to each AOM versus alendronate (Hazard Ratio) in sex strata and calendar periods (before 2011, and from 2011 onwards), in CPRD and BIFAP.

	CPRD					BIFAP				
	Patients at risk	No. VTE cases	HR ^a	95%CI		Patients at risk	No. VTE cases	HR ^a	95%CI	
Before 2011										
Alendronate	103,800	1420	Ref.	-	-	33,948	179	Ref.	-	-
Other Bisphosphonates	27,999	354	1.06	0.94	1.19	34,730	162	0.93	0.75	1.15
Strontium Ranelate	2,389	21	0.93	0.60	1.44	7,016	26	1.09	0.72	1.64
Teriparatide	7	0	-	-	-	856	6	1.64	0.72	3.72
Denosumab	1	0	-	-	-	0	0	NA	NA	NA
From 2011 onwards										
Alendronate	23,321	224	Ref.	-	-	2,234	7	Ref.	-	-
Other Bisphosphonates	1,008	11	1.09	0.59	2.00	2,864	13	1.56	0.62	3.94
Strontium Ranelate	656	4	0.74	0.27	1.99	962	6	1.98	0.65	6.01
Teriparatide	0	0	-	-	-	431	1	0.54	0.07	4.43
Denosumab	28	1	3.49	0.49	24.96	293	1	1.44	0.17	11.81
p for period interaction			p=0.99					p=0.08		
Men										
Alendronate	25,819	447	Ref.	-	-	3,834	29	Ref.	-	-
Other Bisphosphonates	5,244	76	0.87	0.68	1.10	3,862	36	1.25	0.77	2.05
Strontium Ranelate	470	4	0.74	0.28	1.98	787	5	1.19	0.46	3.08
Teriparatide	1	0	-	-	-	250	2	1.29	0.30	5.51
Denosumab	4	0	-	-	-	29	1	9.13	1.21	68.95
Women										
Alendronate	101,302	1,197	Ref.	-	-	32,348	157	Ref.	-	-
Other Bisphosphonates	23,763	289	1.11	0.97	1.26	33,732	139	0.90	0.71	1.13
Strontium Ranelate	2,575	21	0.93	0.61	1.44	7,191	27	1.20	0.79	1.81
Teriparatide	6	0	-	-	-	1,037	5	1.27	0.52	3.11
Denosumab	25	1	3.94	0.55	28.03	264	0	0.00	-	-
p for sex interaction			p=0.19					p=0.83		
50-59y										
Alendronate	15,249	141	Ref.	-	-	8,200	7	Ref.	-	-
Other Bisphosphonates	3,488	33	1.12	0.76	1.63	9,048	17	1.97	0.81	4.78
Strontium Ranelate	173	2	2.21	0.55	9.00	1,878	1	0.84	0.10	6.89
Teriparatide	0	0	-	-	-	151	0	0.00	-	-
Denosumab	2	0	-	-	-	51	0	0.00	-	-
60-69y										
Alendronate	29,537	342	Ref.	-	-	10,387	35	Ref.	-	-
Other Bisphosphonates	6,813	73	1.00	0.77	1.28	11,069	35	0.93	0.58	1.49
Strontium Ranelate	371	3	1.14	0.37	3.57	2,215	5	1.11	0.43	2.86

Teriparatide	2	0	-	-	-	273	2	3.06	0.72	12.96
Denosumab	5	0	-	-	-	86	0	0.00	-	-
70-79y										
Alendronate	42,037	608	Ref.	-	-	11,948	89	Ref.	-	-
Other Bisphosphonates	9,685	144	1.13	0.94	1.36	11,963	82	0.96	0.71	1.30
Strontium Ranelate	776	7	0.91	0.43	1.91	2,452	13	1.10	0.61	1.98
Teriparatide	4	0	-	-	-	505	3	1.35	0.42	4.31
Denosumab	8	0	-	-	-	77	1	5.31	0.73	38.60
80-89y										
Alendronate	40,298	553	Ref.	-	-	5,647	55	Ref.	-	-
Other Bisphosphonates	9,021	115	0.96	0.79	1.80	5,514	41	0.78	0.52	1.17
Strontium Ranelate	1,725	13	0.78	0.45	1.35	1,433	13	1.35	0.73	2.48
Teriparatide	1	0	-	-	-	358	2	0.82	0.20	3.38
Denosumab	14	1	6.44	0.90	46.1	79	0	0.00	-	-
p for age interaction			p=0.51					p=0.21		

^a HR were adjusted as per protocol by age, sex, history of VTE, cancer, peripheral arterial disease, vein insufficiency or phlebitis, recent fractures (recorded during two months before therapy initiation as a proxy for patients who are bed-bound), and hormone replacement therapy prescribed during the year before therapy initiation, BMI and current smoking as recorded during the year of therapy initiation.